Levine Leichtman Capital Partners Portfolio Company Capsa Healthcare Acquires RoboPharma

Capsa Healthcare | August 14, 2020

Levine Leichtman Capital Partners Portfolio Company Capsa Healthcare Acquires RoboPharma
Capsa Healthcare ("Capsa"), a portfolio company of Levine Leichtman Capital Partners ("LLCP"), announced today that it has acquired NewRobo Development B.V. and subsidiaries (collectively, "RoboPharma"). RoboPharma, based in Waalwijk, Netherlands, creates and implements pharmacy automation solutions for some of the largest pharmacies in Europe. Capsa is a leading provider of innovative, highly engineered workflow products that increase efficiency and reduce costs, enhance medication security, and tighten inventory control across healthcare settings worldwide. Capsa's core offerings include mobile workstations, medication management solutions, and pharmacy automation products sold to over 3,000 end customers, including leading health systems, senior care communities, and major retail and institutional pharmacies. Capsa was founded in 1958 and is headquartered in Portland, Oregon with additional production facilities in Columbus, Ohio and Agua Prieta, Mexico.

Spotlight

Drug development and production are challenging, however, high throughput characterization systems can greatly accelerate discovery programs. Using a proprietary discovery and development platform technology, Avitide enables its partners to rapidly advance candidate molecules to the clinic and achieve faster and more predictable bioprocess development timelines.

Related News

KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development

KYAN Therapeutics, Inc. | September 24, 2020

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate Cancer. The low toxicity and metabolic stability of KYAN-001 indicates a better safety and tolerability profile than FDA approved pan-HDAC inhibitors which suffer from toxicity issues and side effects. KYAN-001 also uniquely inhibits HDAC4 nucleoshuttling to further drive its anti-cancer effects.

Read More

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19

Novartis | June 26, 2020

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today. The research – which covered 2,502 tech professionals in the USA, UK, Germany, China and India, conducted between May and June 2020 – targeted respondents from a variety of sectors and organizations with the objective to study perception shifts of the industry in the wake of the global COVID-19 pandemic. For Novartis, a leading global medicines company, investing in and progressing data and digital capabilities is central to its work to reimagine medicine. As the company continues to grow its team of world-leading tech talent, through partnerships and hires, the research explored whether those in tech are aware of role they could play in helping to solve the world’s biggest medicine challenges now and in the future.

Read More

Coronavirus tracker: GSK, Sanofi burned by Warp Speed picks; EU members launch COVID vax alliance

Fiercepharma | June 04, 2020

The Trump administration unveiled its finalists for Operation Warp Speed on Wednesday afternoon, with a notable Big Pharma bent. Meanwhile, Novavax—whose shot did not make the cut—recruited Japanese manufacturer AGC Biologics to churn out adjuvant for its coronavirus vaccine candidate. And on the heels of a controversial report by the Lancet, the New England Journal of Medicine published data showing hydroxychloroquine didn't do much to prevent infection in people exposed to the virus. But that didn't stop the World Health Organization from resuming trials on the antimalarial, which were halted last week over safety concerns. Plus, four European countries forged a new vaccine alliance to bring COVID shots to the continent, taking cues from a U.S. agency, the Biomedical Advanced Research and Development Authority, as more countries aim to secure supplies to fight the pandemic.

Read More

Spotlight

Drug development and production are challenging, however, high throughput characterization systems can greatly accelerate discovery programs. Using a proprietary discovery and development platform technology, Avitide enables its partners to rapidly advance candidate molecules to the clinic and achieve faster and more predictable bioprocess development timelines.